{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:35:16Z","timestamp":1762540516514},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":822,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Liver Disease"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1002\/cld.209","type":"journal-article","created":{"date-parts":[[2013,6,21]],"date-time":"2013-06-21T20:53:00Z","timestamp":1371847980000},"page":"136-139","source":"Crossref","is-referenced-by-count":2,"title":["Current treatment strategies for hepatorenal syndrome"],"prefix":"10.1097","volume":"2","author":[{"given":"Elsa","family":"Sol\u00e0","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Gin\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2013,6,21]]},"reference":[{"key":"10.1002\/cld.209-BIB1|cit1","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.ajkd.2011.12.032","article-title":"Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis","volume":"59","author":"Fagundes","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1002\/cld.209-BIB2|cit2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2008-1040323","article-title":"Pathogenesis and treatment of hepatorenal syndrome","volume":"28","author":"Arroyo","year":"2008","journal-title":"Semin Liver Dis"},{"key":"10.1002\/cld.209-BIB3|cit3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jhep.2012.03.015","article-title":"Urinary neutrophil gelatinase-lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis","volume":"57","author":"Fagundes","year":"2012","journal-title":"J Hepatol"},{"key":"10.1002\/cld.209-BIB4|cit4","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1007\/s10620-012-2180-x","article-title":"Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis","volume":"57","author":"Verna","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1002\/cld.209-BIB5|cit5","first-page":"1310","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis","volume":"56","author":"Salerno","year":"2007","journal-title":"Gut"},{"key":"10.1002\/cld.209-BIB6|cit6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","article-title":"EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis","volume":"53","author":"Gin\u00e8s","year":"2010","journal-title":"J Hepatol"},{"key":"10.1002\/cld.209-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A prospective, randomized, double blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS)","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/cld.209-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study","volume":"134","author":"Mart\u00edn-Llah\u00ed","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/cld.209-BIB9|cit9","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hep.23286","article-title":"Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome","volume":"51","author":"Gluud","year":"2010","journal-title":"Hepatology"},{"key":"10.1002\/cld.209-BIB10|cit10","first-page":"378A","article-title":"Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type-1 hepatorenal syndrome (HRS) in patients with cirrhosis: results of a controlled clinical trial","volume":"48","author":"Angeli","year":"2008","journal-title":"Hepatology"},{"key":"10.1002\/cld.209-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/j.gastro.2009.03.064","article-title":"Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration","volume":"137","author":"Gerbes","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/cld.209-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","article-title":"Noradrenaline vs terlipressin in the treatment of hepatorenal syndrome: a randomized study","volume":"56","author":"Singh","year":"2012","journal-title":"J Hepatol"},{"key":"10.1002\/cld.209-BIB13|cit13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.20262","article-title":"Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome","volume":"40","author":"Wong","year":"2004","journal-title":"Hepatology"},{"key":"10.1002\/cld.209-BIB14|cit14","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s10620-006-9312-0","article-title":"Octreotide\/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome","volume":"52","author":"Esrailian","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1002\/cld.209-BIB15|cit15","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/MCG.0b013e318188947c","article-title":"Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome","volume":"43","author":"Skagen","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1002\/cld.209-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/TP.0b013e31821690bf","article-title":"Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin","volume":"91","author":"Rice","year":"2011","journal-title":"Transplantation"},{"key":"10.1002\/cld.209-BIB17|cit17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/hep.510280219","article-title":"Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems","volume":"28","author":"Guevara","year":"1998","journal-title":"Hepatology"},{"key":"10.1002\/cld.209-BIB18|cit18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/gut.47.2.288","article-title":"Long term outcome after transjugular intrahepatic portosystemic stent-shunt in nontransplant cirrhotics with hepatorenal syndrome: a phase II study","volume":"47","author":"Brensing","year":"2000","journal-title":"Gut"},{"key":"10.1002\/cld.209-BIB19|cit19","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2011.12.056","article-title":"Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure","volume":"142","author":"Kribben","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1002\/cld.209-BIB20|cit20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/lt.21877","article-title":"Report of the first international Liver Transplantation Society expert panel consensus conference on renal insufficiency in liver transplantation","volume":"15","author":"Charlton","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1002\/cld.209-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhep.2012.06.024","article-title":"Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice","volume":"57","author":"Angeli","year":"2012","journal-title":"J Hepatol"}],"container-title":["Clinical Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcld.209","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/cld.209\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T11:21:33Z","timestamp":1673954493000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cld.209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"URL":"https:\/\/doi.org\/10.1002\/cld.209","relation":{},"ISSN":["2046-2484"],"issn-type":[{"value":"2046-2484","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}